The nanoparticles as drug carriers have demonstrated enhanced targeting, and sustained/-
controlled drug release, as evident from numerous investigations that have shown promising outcomes
facilitating the wellbeing of humans in the desired manner. The lipid-based nanoparticles
are biodegradable and considered biocompatible by virtue of being composed of lipid moieties
mimicking physiological lipids of biological systems which is their prime advantage over the other
polymeric systems. A variety of such lipid carriers have been reported to be delivered from the parenteral
route. However, there are certain pitfalls which are associated with lipid nanoparticles such
as toxicity, poor scale up potential, immunological reactions and absence of straight forward regulatory
guidelines that address the issues of lipoidal nanocarriers such as their classification, approval
and compliance of governmental policies. Therefore attention must be given to address the technological
and regulatory challenges associated with lipoidal nano-formulations for parenteral administration
to smoothen the approval process throughout the world and bringing the same to the terminal
users on time.
Keywords: Lipids carriers, nanotechnology, parenteral route, regulatory challenges, lipid nanoparticulates, lipoidal nanocarriers.
Rights & PermissionsPrintExport